Clinical Trial: NCT04395677
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Nuvation Bio Inc. |
| Information Provided By: | Nuvation Bio Inc. |
| Last Update Posted: | 2026-02-06 |
Study Overview
Brief Summary
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Official Title
A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
Conditions
Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: AB-106
Other Study ID Numbers
- AB-106-C203
Start Date (Actual)
2020-07-07
Primary Completion Date (Actual)
2024-06-07
Study Completion Date (Estimated)
2027-06
Enrollment (Actual)
173
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Nuvation Bio Inc. |
| Information Provided By: | Nuvation Bio Inc. |
| Last Update Posted: | 2026-02-06 |
Study Overview
Brief Summary
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Official Title
A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
Conditions
Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: AB-106
Other Study ID Numbers
- AB-106-C203
Start Date (Actual)
2020-07-07
Primary Completion Date (Actual)
2024-06-07
Study Completion Date (Estimated)
2027-06
Enrollment (Actual)
173
Study Type
Interventional
Phase
Phase 2